Vypadalo to jako příběh zázračného úspěchu. Cena akcií společnosti Novo Nordisk vyrábějící léky na cukrovku a hubnutí ...

Léky na hubnutí, jako je například Ozempic, zažívají v Americe obrovský boom a rostoucí zájem o ně je patrný i v Česku. Lidé ...

Léky jako Ozempic, Wegovy, Mounjaro či Zepbound na bázi účinných látek semaglutid a tirzepatid přinesly pokrok při léčbě ...

Weight-loss drugs can be life-changing for people who have struggled to lose weight, however, some people who take them experience unpleasant and concerning side effects. In 2024, roughly 5 per ...

Primárně byl ale lék Ozempic vyvinut pro léčbu cukrovky 2. typu. Léky Saxenda a Wegovy jsou určené k léčbě obezity a Mounjaro navíc ještě k léčbě diabetu. Léky tohoto typu fungují na hormonálních ...

John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access to GLP-1 medications, such as Ozempic and Wegovy, for millions of Medicare ...

The rise of weight-loss drugs like Ozempic and Wegovy have upended WeightWatchers business model, which was based around selling low-calorie foods and diet advice to overweight people.

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs ...

This was a mistake. These drugs, like Ozempic and Wegovy, can be a game changer.” Fetterman says he has lost 20 pounds and is not being paid for discussing his treatment. “I’m just a guy who ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

“This was a mistake.” Fetterman made it clear that he was not receiving any money for his opinion, and wrote that he believes drugs like Mounjaro, Ozempic and Wegovy are a “game changer.

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes ...